Depression Therapeutics Market, Drug Type (Antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Serotonin Modulators, Tricyclic & Tetracyclic Antidepressants and Atypical Antidepressants), Antipsychotics and Others), by Indication (Major Depressive Disorder (MDD), Bipolar Disorder, Dysthymic Disorder, Postpartum Depression, Seasonal Affective Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Trends, and Forecast 2018 - 2026
- Report code : CMI61307 |
- Industry :
Pharmaceutical
- Published On : Jul 2019 |
- Pages : 171 Pages |
- Format :
Depression Therapeutics Market - Insights
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and serotonin receptor modulators (SRMs). These medications exhibit different pharmacological action in the brain once administered to regain the chemical balance in the brain, associated with behavioral disorders such as depression. Commercially available antidepressants include Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil), Vilazodone (Viibryd), Sertraline (Zoloft), Venlafaxine (Effexor), Levomilnacipran (Fetzima), Aripiprazole (Abilify), and Vortioxetine (Trintellix).
Rising prevalence of mental disorders such as depression and anxiety is expected to boost the depression therapeutics market growth over the forecast period
Mental disorders such as major depressive disorder, anxiety, and associated co-morbidities have high global prevalence. According to the World Health Organization (WHO), in 2017, around 300 million people are estimated to be affected with depression, globally. Furthermore, WHO passed a World Health Assembly resolution in 2013, to address mental disorders in a comprehensive and coordinated manner and has covered depression under its Mental Health Gap Action Program. According to Anxiety & Depression Association of America (ADAA), major depressive disorder is the leading cause of disability in the U.S., among people aged between 15 years and 44.3 years, and affects around 6.7% of the U.S. population aged 18 years and above. Furthermore, according to a report published by Italian Medicines Agency, in 2013, the consumption of antidepressants rose by 4.5% in Italy between 2004 and 2012, which is attributed to rising prevalence of depression and high availability of generic medicines in the country. According to World Health Organization (WHO), in 2015, top five mental problems in the Asia Pacific region are depression, anxiety, post-traumatic stress disorder (PTSD), suicidal behavior, and substance abuse disorder. As the prevalence of mental disorders increases, the consumption of depression drugs is also expected to increase over the forecast period.
The global depression therapeutics market size was valued at US$ 11,130.7 million in 2017 and is expected to witness a CAGR of 3.7% over the forecast period (2018–2026).
Figure No.1: Global Depression Therapeutics Market Share, By Drug Type (%), 2018 & 2026
Source: Coherent Market Insights Analysis (2018)
Low costs of antidepressant medication along with lack of affordable alternative therapies are expected to boost the global depression therapeutics market growth over the forecast period
Mental disorders such as depression and anxiety are treated either with medication or psychotherapy, which involves cognitive behavioral therapy (CBT). According to American Psychiatric Association, 2017, although both the therapies exhibit similar levels of effectiveness with 30% to 40% remission rates, the cost-effectiveness of these therapies plays an important role. Patients often do not get access to advanced psychotherapy due to lack of resources, social stigma associated with mental disorders, and lack of skilled psychotherapists, wherein, medication proves to be useful. Antidepressants are widely available due to high presence of generic drug manufacturers, who offer cost-effective drugs, whereas, cost for psychotherapy is relatively higher and is unavailable everywhere due to lack of skilled psychiatrists. According to Psychotherapy and Counselling Federation of Australia (PACFA), costs for psychotherapy single session range from US$ 60 to US$ 150, whereas, costs for one branded drug tablet ranges from around US$ 5 to US$ 10. Newer treatment options include brain stimulation therapies such as electroconvulsive therapy and vagus nerve stimulation, which are not widely available and are expensive as well. For instance, Fisher Wallace, created a U.S. FDA approved stimulator, Fisher Wallace Stimulator to treat depression, anxiety, and insomnia, costing around US$ 700, which majority of the population cannot afford.
Figure No.2: Global Depression Therapeutics Market Share, By Region (%), 2018 & 2026
Various side effects such as increased suicidal tendency, sexual dysfunction and anxiety has limited the adoption of depression drugs. Moreover, due to these side effects manufacturers have been dragged in court many a times which has demotivated them to invest more in this market. For instance, in 2017, GlaxoSmithKline Plc was asked to pay US$ 3 Mn to a woman whose husband committed suicide after taking generic version of Paxil, an antidepressant drug, even though the generic drug was manufactured by another company, Mylan N.V. The jury ruled that since GlaxoSmithKline plc controls the drug’s design and label, applied to both generic and branded, the company is liable and will have to pay US$ 3 Mn to the complainant.
Some major players operating in the depression therapeutics market are Pfizer, Inc., Eli, Lilly and Company, AstraZeneca, Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd, and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
Antidepressants are prescribed in serious to mild mental health conditions such as major depression and anxiety. Antidepressant drug category is highly lucrative due to low availability of alternative drug therapies for treatment of such disorders. Drug manufacturers are increasingly advancing the antidepressant drug category by introducing innovative therapies such as selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Depression is one of the most common mental disorders, which are primarily treated by antidepressants. According to National Health Service Digital (NHS Digital), UK, antidepressant medication prescriptions observed the largest increase in 2016.
Market Dynamics
The global depression therapeutics market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs are losing patent protection due to which increasing number of generic manufacturers are developing product variations, this in turn is boosting the growth of the market. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as depression are fueling growth of the market. However, life threatening side effects associated with these medications as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the depression therapeutics market.
Key features of the study:
- This report provides in-depth analysis of the global depression therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global depression therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key companies covered as a part of this study include Pfizer, Inc., Eli, Lilly and Company, AstraZeneca, Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co., Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd, and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global depression therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global depression therapeutics market
Detailed Segmentation:
- Global Depression Therapeutics Market, By Drug Type:
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- Global Depression Therapeutics Market, By Indication:
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- Global Depression Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Global Depression Therapeutics Market, By Geography:
- North America
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- U.S.
- Canada
- Europe
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others
- By Indication
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Company Profiles
- Pfizer, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Eily, Lilly, and Company
- AstraZeneca, Plc
- Allergan Plc
- GlaxoSmithKline Plc
- Intellipharmaceutics International, Inc.
- Takeda Pharmaceutical Company Limited
- H.Lundbeck A/S
- Otsuka Holdings Co. Ltd.
- Apotex, Inc.
- Shionogi & Co. Ltd.
- Zhejiang Hua Hai Pharmaceutical Co., Ltd
- Chengdu Kanghong Pharmaceutical Group Co. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- PEST Analysis
- Porter’s Five Forces Analysis
- Pipeline Analysis
- Global Depression Therapeutics Market, By Drug Type, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Global Depression Therapeutics Market, By Indication, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Major Depressive Disorder (MDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Dysthymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Postpartum Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Seasonal Affective Disorder (SAD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Premenstrual Dysphoric Disorder (PMDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Global Depression Therapeutics Market, By Distribution Channel, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2026, (US$ Mn)
- Global Depression Therapeutics Market, By Regions, 2018–2026, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2018–2026, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2018–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2018–2026 (US$ Mn)
- South Africa
- North Africa
- Central Africa
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eily, Lilly, and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca, Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intellipharmaceutics International, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- H.Lundbeck A/S
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Holdings Co. Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shionogi & Co. Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zhejiang Hua Hai Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chengdu Kanghong Pharmaceutical Group Co. Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Section
- References
- Research Methodology
- About Us and Sales Contact
*Browse 34 market data tables and 28 figures on "Depression Therapeutics Market - Global forecast to 2026”.
Related Insights :
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.